CARB-X News

• 03.04.2026  |  CARB-X provides funding to Myers Research Group to develop antibiotic targeting drug-resistant pathogens

  CARB-X is awarding US$1.2 million to the Andrew G. Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop enhanced antibiotics that target multi-drug-resistant Gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia, and bloodstream infections.

  Full Story

• 02.26.2026  |  CARB-X launches 2026 funding round to address global burden of AMR

  CARB-X announced today a funding solicitation targeting the global burden of antimicrobial resistance (AMR).

  Full Story

• 02.05.2026  |  CARB-X to support development of typhoid fever diagnostic from Chembio

  CARB-X is awarding US$1.8million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi.

  Full Story

• 01.28.2026  |  Wellcome renews AMR innovation partnership with CARB-X with US$60M award

  CARB-X announced today its renewed partnership with Wellcome, a global charitable foundation which co-founded CARB-X in 2016. Between 2026 and 2028, Wellcome will provide CARB-X with new funding of up to US$60 million to support early-stage research and development of innovative antibacterial products to protect lives from bacterial infections globally.

  Full Story

• 01.08.2026  |  CARB-X announces new chemistry-focused theme ahead of 2026 funding call

  CARB-X is seeking applications for novel chemistry plans against known antimicrobial resistance (AMR) targets. The aim is to unlock innovative starting points for therapeutics to address dangerous, drug-resistant bacterial infections.

  Full Story